{ "instance": { "f20f2021_xtlbiopharma.htm": { "axisCustom": 6, "axisStandard": 11, "contextCount": 146, "dts": { "calculationLink": { "local": [ "xtlb-20211231_cal.xml" ] }, "definitionLink": { "local": [ "xtlb-20211231_def.xml" ] }, "inline": { "local": [ "f20f2021_xtlbiopharma.htm" ] }, "labelLink": { "local": [ "xtlb-20211231_lab.xml" ] }, "presentationLink": { "local": [ "xtlb-20211231_pre.xml" ] }, "schema": { "local": [ "xtlb-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd" ] } }, "elementCount": 496, "entityCount": 1, "hidden": { "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 47, "http://xbrl.sec.gov/dei/2021q4": 5, "http://xtlb.com/20211231": 42, "total": 94 }, "keyCustom": 130, "keyStandard": 164, "memberCustom": 32, "memberStandard": 10, "nsprefix": "xtlb", "nsuri": "http://xtlb.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://xtlb.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Financial Instruments and Financial Risk Management", "role": "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement", "shortName": "Financial Instruments and Financial Risk Management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Cash and Cash Equivalents", "role": "http://xtlb.com/role/CashandCashEquivalents", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfMarketableSecuritiesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Marketable Securities - InterCure Ltd", "role": "http://xtlb.com/role/MarketableSecuritiesInterCureLtd", "shortName": "Marketable Securities - InterCure Ltd", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfMarketableSecuritiesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfPrepaidExpensesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://xtlb.com/role/PrepaidExpensesandOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfPrepaidExpensesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Intangible Assets", "role": "http://xtlb.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfOtherAccountsPayablesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Accounts Payable", "role": "http://xtlb.com/role/AccountsPayable", "shortName": "Accounts Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfOtherAccountsPayablesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Employee Benefit Liabilities", "role": "http://xtlb.com/role/EmployeeBenefitLiabilities", "shortName": "Employee Benefit Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:WarrantsAtFairValueOfExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Warrants", "role": "http://xtlb.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:WarrantsAtFairValueOfExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Commitments", "role": "http://xtlb.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ShareCapitalReservesAndRetainedEarnings", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Share Capital, Reserves and Retained Earnings", "role": "http://xtlb.com/role/ShareCapitalReservesandRetainedEarnings", "shortName": "Share Capital, Reserves and Retained Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ShareCapitalReservesAndRetainedEarnings", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Statements of Financial Position", "role": "http://xtlb.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Statements of Financial Position", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherCurrentReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Share-Based Payment", "role": "http://xtlb.com/role/ShareBasedPayment", "shortName": "Share-Based Payment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Research and Development Expenses", "role": "http://xtlb.com/role/ResearchandDevelopmentExpenses", "shortName": "Research and Development Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - General and Administrative Expenses", "role": "http://xtlb.com/role/GeneralandAdministrativeExpenses", "shortName": "General and Administrative Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Finance Income (Expenses), Net", "role": "http://xtlb.com/role/FinanceIncomeExpensesNet", "shortName": "Finance Income (Expenses), Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Taxes on Income", "role": "http://xtlb.com/role/TaxesonIncome", "shortName": "Taxes on Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Transactions and Balances with Related Parties", "role": "http://xtlb.com/role/TransactionsandBalanceswithRelatedParties", "shortName": "Transactions and Balances with Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Earnings (Loss) Per Share", "role": "http://xtlb.com/role/EarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Subsequent Events", "role": "http://xtlb.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DescriptionOfAccountingPolicyForBasisOfPresentationOfFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://xtlb.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DescriptionOfAccountingPolicyForBasisOfPresentationOfFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutExchangeRateExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://xtlb.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutExchangeRateExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unique": true, "unitRef": "ilsPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Statements of Financial Position (Parentheticals)", "role": "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Statements of Financial Position (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unique": true, "unitRef": "ilsPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfChangesInFinancialLiabilitiesFromFinanceActivitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Financial Instruments and Financial Risk Management (Tables)", "role": "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables", "shortName": "Financial Instruments and Financial Risk Management (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfChangesInFinancialLiabilitiesFromFinanceActivitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Cash and Cash Equivalents (Tables)", "role": "http://xtlb.com/role/CashandCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Marketable Securities - InterCure Ltd (Tables)", "role": "http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables", "shortName": "Marketable Securities - InterCure Ltd (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://xtlb.com/role/PrepaidExpensesandOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Accounts Payable (Tables)", "role": "http://xtlb.com/role/AccountsPayableTables", "shortName": "Accounts Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Warrants (Tables)", "role": "http://xtlb.com/role/WarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Share-Based Payment (Tables)", "role": "http://xtlb.com/role/ShareBasedPaymentTables", "shortName": "Share-Based Payment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Research and Development Expenses (Tables)", "role": "http://xtlb.com/role/ResearchandDevelopmentExpensesTables", "shortName": "Research and Development Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - General and Administrative Expenses (Tables)", "role": "http://xtlb.com/role/GeneralandAdministrativeExpensesTables", "shortName": "General and Administrative Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Finance Income (Expenses), Net (Tables)", "role": "http://xtlb.com/role/FinanceIncomeExpensesNetTables", "shortName": "Finance Income (Expenses), Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "role": "http://xtlb.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfIncomeTaxExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Taxes on Income (Tables)", "role": "http://xtlb.com/role/TaxesonIncomeTables", "shortName": "Taxes on Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfIncomeTaxExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Transactions and Balances with Related Parties (Tables)", "role": "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables", "shortName": "Transactions and Balances with Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfProfitlossAttributedToOrdinaryShareholdersbasicTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Earnings (Loss) Per Share (Tables)", "role": "http://xtlb.com/role/EarningsLossPerShareTables", "shortName": "Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfProfitlossAttributedToOrdinaryShareholdersbasicTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "xtlb:DisclosureOfDetailedInformationAboutExchangeRateExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Significant Accounting Policies (Details) - Schedule of exchange rate of the U.S. dollar in relation to the NIS", "role": "http://xtlb.com/role/ScheduleofexchangerateoftheUSdollarinrelationtotheNISTable", "shortName": "Significant Accounting Policies (Details) - Schedule of exchange rate of the U.S. dollar in relation to the NIS", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "xtlb:DisclosureOfDetailedInformationAboutExchangeRateExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c34", "decimals": "2", "first": true, "lang": null, "name": "xtlb:PropertyAndEquipmentUsefulLifePercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment", "role": "http://xtlb.com/role/ScheduleofdepreciationofpropertyandequipmentTable", "shortName": "Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c34", "decimals": "2", "first": true, "lang": null, "name": "xtlb:PropertyAndEquipmentUsefulLifePercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DescriptionOfForeignCurrencyExchangeRateRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Financial Instruments and Financial Risk Management (Details)", "role": "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails", "shortName": "Financial Instruments and Financial Risk Management (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DescriptionOfForeignCurrencyExchangeRateRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfChangesInFinancialLiabilitiesFromFinanceActivitiesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c39", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Financial Instruments and Financial Risk Management (Details) - Schedule of changes in financial liabilities from finance activities", "role": "http://xtlb.com/role/ScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable", "shortName": "Financial Instruments and Financial Risk Management (Details) - Schedule of changes in financial liabilities from finance activities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfChangesInFinancialLiabilitiesFromFinanceActivitiesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c35", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "xtlb:DepositsWithMaturity", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DepositsWithMaturity", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Cash and Cash Equivalents (Details)", "role": "http://xtlb.com/role/CashandCashEquivalentsDetails", "shortName": "Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "xtlb:DepositsWithMaturity", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DepositsWithMaturity", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashOnHand", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents", "role": "http://xtlb.com/role/ScheduleofcashandcashequivalentsTable", "shortName": "Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashOnHand", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:CashAndCashEquivalent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents are denominated or linked", "role": "http://xtlb.com/role/ScheduleofcashandcashequivalentsaredenominatedorlinkedTable", "shortName": "Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents are denominated or linked", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c46", "decimals": "-3", "lang": null, "name": "xtlb:CashAndCashEquivalent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c26", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Changes in Equity", "role": "http://xtlb.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statements of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c26", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "xtlb:PercentageOfHoldingShare", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Marketable Securities - InterCure Ltd (Details)", "role": "http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails", "shortName": "Marketable Securities - InterCure Ltd (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "xtlb:PercentageOfHoldingShare", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Marketable Securities - InterCure Ltd (Details) - Schedule of financial instruments", "role": "http://xtlb.com/role/ScheduleoffinancialinstrumentsTable", "shortName": "Marketable Securities - InterCure Ltd (Details) - Schedule of financial instruments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsAvailableforsale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Marketable Securities - InterCure Ltd (Details) - Schedule of changes in marketable securities", "role": "http://xtlb.com/role/ScheduleofchangesinmarketablesecuritiesTable", "shortName": "Marketable Securities - InterCure Ltd (Details) - Schedule of changes in marketable securities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsAvailableforsale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:GovernmentAuthorities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets", "role": "http://xtlb.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable", "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:GovernmentAuthorities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:LicenseAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Intangible Assets (Details)", "role": "http://xtlb.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:LicenseAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Accounts Payable (Details) - Schedule of composition of accounts payable", "role": "http://xtlb.com/role/ScheduleofcompositionofaccountspayableTable", "shortName": "Accounts Payable (Details) - Schedule of composition of accounts payable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:OtherCurrentPayables", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Accounts Payable (Details) - Schedule of carrying amount of other accounts payable", "role": "http://xtlb.com/role/ScheduleofcarryingamountofotheraccountspayableTable", "shortName": "Accounts Payable (Details) - Schedule of carrying amount of other accounts payable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c54", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherCurrentPayables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Employee Benefit Liabilities (Details)", "role": "http://xtlb.com/role/EmployeeBenefitLiabilitiesDetails", "shortName": "Employee Benefit Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c58", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:GrossFundRaised", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Warrants (Details)", "role": "http://xtlb.com/role/WarrantsDetails", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c58", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:GrossFundRaised", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants", "role": "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable", "shortName": "Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "role": "http://xtlb.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "lang": null, "name": "xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfTheOutstandingWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "xtlb:WarrantsOutstandingToPurchaseADSs", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Warrants (Details) - Schedule of the outstanding warrants", "role": "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable", "shortName": "Warrants (Details) - Schedule of the outstanding warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfTheOutstandingWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "xtlb:WarrantsOutstandingToPurchaseADSs", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfWarrantExercisesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c70", "decimals": "0", "first": true, "lang": null, "name": "xtlb:NumberOfWarrantsOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Warrants (Details) - Schedule of warrant exercises", "role": "http://xtlb.com/role/ScheduleofwarrantexercisesTable", "shortName": "Warrants (Details) - Schedule of warrant exercises", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfWarrantExercisesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c70", "decimals": "0", "first": true, "lang": null, "name": "xtlb:NumberOfWarrantsOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c74", "decimals": "2", "first": true, "lang": null, "name": "xtlb:PercentageOfObligationToPayRoyalties", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Commitments (Details)", "role": "http://xtlb.com/role/CommitmentsDetails", "shortName": "Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c74", "decimals": "2", "first": true, "lang": null, "name": "xtlb:PercentageOfObligationToPayRoyalties", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:OrdinarySharesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Share Capital, Reserves and Retained Earnings (Details)", "role": "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails", "shortName": "Share Capital, Reserves and Retained Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:OrdinarySharesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c79", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:IncreaseOfReserveDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Share-Based Payment (Details)", "role": "http://xtlb.com/role/ShareBasedPaymentDetails", "shortName": "Share-Based Payment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c79", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:IncreaseOfReserveDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c80", "decimals": "0", "first": true, "lang": null, "name": "xtlb:NumberOfOutstandingShareOptionsInShareBasedPaymentArrangement", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Share-Based Payment (Details) - Schedule of number of share options and their related weighted average exercise prices", "role": "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable", "shortName": "Share-Based Payment (Details) - Schedule of number of share options and their related weighted average exercise prices", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c82", "decimals": "0", "lang": null, "name": "xtlb:NumberOfOutstandingShareOptionsInShareBasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c87", "decimals": "0", "first": true, "lang": null, "name": "xtlb:NumberOfOutstandingShareOptionsInShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Share-Based Payment (Details) - Schedule of exercise price and the remaining contractual life (in years)", "role": "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable", "shortName": "Share-Based Payment (Details) - Schedule of exercise price and the remaining contractual life (in years)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c87", "decimals": "0", "first": true, "lang": null, "name": "xtlb:NumberOfOutstandingShareOptionsInShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c83", "decimals": "0", "first": true, "lang": null, "name": "xtlb:OptionsOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Share-Based Payment (Details) - Schedule of outstanding options", "role": "http://xtlb.com/role/ScheduleofoutstandingoptionsTable", "shortName": "Share-Based Payment (Details) - Schedule of outstanding options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c83", "decimals": "0", "first": true, "lang": null, "name": "xtlb:OptionsOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutFairValueOptionsGrantedForWeightedAverageAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c117", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Share-Based Payment (Details) - Schedule of detailed information about the fair value for options granted", "role": "http://xtlb.com/role/ScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable", "shortName": "Share-Based Payment (Details) - Schedule of detailed information about the fair value for options granted", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutFairValueOptionsGrantedForWeightedAverageAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c117", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:FeesRelatedToServiceProviders", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Research and Development Expenses (Details) - Schedule of research and development expenses", "role": "http://xtlb.com/role/ScheduleofresearchanddevelopmentexpensesTable", "shortName": "Research and Development Expenses (Details) - Schedule of research and development expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:FeesRelatedToServiceProviders", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - General", "role": "http://xtlb.com/role/General", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - General and Administrative Expenses (Details) - Schedule of general and administrative expenses", "role": "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable", "shortName": "General and Administrative Expenses (Details) - Schedule of general and administrative expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:RevaluationOfWarrantsToPurchaseExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Finance Income (Expenses), Net (Details) - Schedule of finance income (expenses), net", "role": "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable", "shortName": "Finance Income (Expenses), Net (Details) - Schedule of finance income (expenses), net", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:RevaluationOfWarrantsToPurchaseExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c118", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Taxes on Income (Details)", "role": "http://xtlb.com/role/TaxesonIncomeDetails", "shortName": "Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c118", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfIncomeTaxExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Taxes on Income (Details) - Schedule of reconciliation between the \u201ctheoretical\u201d tax expense", "role": "http://xtlb.com/role/ScheduleofreconciliationbetweenthetheoreticaltaxexpenseTable", "shortName": "Taxes on Income (Details) - Schedule of reconciliation between the \u201ctheoretical\u201d tax expense", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfIncomeTaxExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Transactions and Balances with Related Parties (Details)", "role": "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails", "shortName": "Transactions and Balances with Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:BenefitsPaidOrPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of compensation to key management personnel for employee services", "role": "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable", "shortName": "Transactions and Balances with Related Parties (Details) - Schedule of compensation to key management personnel for employee services", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:BenefitsPaidOrPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Earnings (Loss) Per Share (Details)", "role": "http://xtlb.com/role/EarningsLossPerShareDetails", "shortName": "Earnings (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfProfitlossAttributedToOrdinaryShareholdersbasicTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of profit (loss) attributed to ordinary shareholders (basic)", "role": "http://xtlb.com/role/ScheduleofprofitlossattributedtoordinaryshareholdersbasicTable", "shortName": "Earnings (Loss) Per Share (Details) - Schedule of profit (loss) attributed to ordinary shareholders (basic)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfProfitlossAttributedToOrdinaryShareholdersbasicTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfWeightedaverageNumberOfOrdinarySharesbasicTableTexBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "xtlb:IssuedOrdinarySharesAtJanuary1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of weighted-average number of ordinary shares (basic)", "role": "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable", "shortName": "Earnings (Loss) Per Share (Details) - Schedule of weighted-average number of ordinary shares (basic)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfWeightedaverageNumberOfOrdinarySharesbasicTableTexBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "xtlb:IssuedOrdinarySharesAtJanuary1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:OtherComprehensiveIncomeBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of profit (loss) attributed to ordinary shareholders (diluted)", "role": "http://xtlb.com/role/ScheduleofprofitlossattributedtoordinaryshareholdersdilutedTable", "shortName": "Earnings (Loss) Per Share (Details) - Schedule of profit (loss) attributed to ordinary shareholders (diluted)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:OtherComprehensiveIncomeBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Significant Accounting Policies", "role": "http://xtlb.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c142", "decimals": "INF", "first": true, "lang": null, "name": "xtlb:WeightedaverageNumberOfOrdinarySharesbasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of weighted-average number of ordinary shares (diluted)", "role": "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesdilutedTable", "shortName": "Earnings (Loss) Per Share (Details) - Schedule of weighted-average number of ordinary shares (diluted)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c142", "decimals": "INF", "first": true, "lang": null, "name": "xtlb:WeightedaverageNumberOfOrdinarySharesbasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c145", "decimals": "0", "first": true, "lang": null, "name": "xtlb:WarrantsExpired", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080 - Disclosure - Subsequent Events (Details)", "role": "http://xtlb.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c145", "decimals": "0", "first": true, "lang": null, "name": "xtlb:WarrantsExpired", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Critical Accounting Estimates and Judgments", "role": "http://xtlb.com/role/CriticalAccountingEstimatesandJudgments", "shortName": "Critical Accounting Estimates and Judgments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r120", "r121", "r122" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r120", "r121", "r122" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r120", "r121", "r122" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r121", "r122" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]", "terseLabel": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name", "terseLabel": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard", "terseLabel": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r120", "r121", "r122" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement", "terseLabel": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report", "terseLabel": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r120", "r121", "r122" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AccountingProfit": { "auth_ref": [ "r36", "r37" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Accounting profit", "terseLabel": "Income (loss) before taxes on income, as reported in the statements of comprehensive income (loss)" } } }, "localname": "AccountingProfit", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofreconciliationbetweenthetheoreticaltaxexpenseTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccrualsClassifiedAsCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://xtlb.com/role/ScheduleofcompositionofaccountspayableTable": { "order": 2.0, "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } }, "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } } }, "localname": "AccrualsClassifiedAsCurrent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompositionofaccountspayableTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionalPaidinCapital": { "auth_ref": [ "r14" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } }, "en-us": { "role": { "label": "Additional paid-in capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidinCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionalPaidinCapitalMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } }, "en-us": { "role": { "label": "Additional paid-in capital [member]", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidinCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_AdjustedWeightedAverageShares": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Diluted weighted average number of ordinary shares (in Shares)" } } }, "localname": "AdjustedWeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": { "auth_ref": [ "r66" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other operating receivables", "terseLabel": "Decrease (increase) in prepaid expenses" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r66" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "terseLabel": "Increase (decrease) in accounts payable" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "auth_ref": [ "r68" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments to reconcile profit (loss)", "totalLabel": "Net operating asset and liability" } } }, "localname": "AdjustmentsForReconcileProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r67" ], "calculation": { "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable": { "order": 3.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based payments" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "auth_ref": [ "r46", "r49" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts payable, related party transactions", "terseLabel": "Amounts of related parties linked to NIS" } } }, "localname": "AmountsPayableRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "Corporate tax rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r14", "r85", "r86", "r88", "r109", "r111" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r55", "r56" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic earnings (loss) per share (in U.S. dollars): (in Dollars per share)" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "ifrs-full_BenefitsPaidOrPayable": { "auth_ref": [ "r52" ], "calculation": { "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable": { "order": 1.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of benefits paid or payable for retirement benefit plans." } }, "en-us": { "role": { "label": "Benefits paid or payable", "terseLabel": "Salaries, management and consulting fees and other short-term benefits" } } }, "localname": "BenefitsPaidOrPayable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BorrowingsInterestRate": { "auth_ref": [ "r105" ], "lang": { "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Interest rate per annum" } } }, "localname": "BorrowingsInterestRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r89", "r90", "r91", "r95", "r105", "r113" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Bottom of range [member]" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsDetails", "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable", "http://xtlb.com/role/ScheduleofwarrantexercisesTable", "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r13", "r72", "r83" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at beginning of year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet", "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r62", "r74" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r62", "r74" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r62", "r74" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperations": { "auth_ref": [ "r68", "r75" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } }, "en-us": { "role": { "label": "Cash flows from (used in) operations", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "CashFlowsFromUsedInOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashOnHand": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash held by the entity. This does not include demand deposits." } }, "en-us": { "role": { "label": "Cash on hand", "terseLabel": "Cash in banks and on hand" } } }, "localname": "CashOnHand", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r48" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails", "http://xtlb.com/role/ScheduleofoutstandingoptionsTable", "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r101", "r102", "r103", "r104" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcashandcashequivalentsaredenominatedorlinkedTable" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r101", "r102", "r103", "r104" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcashandcashequivalentsaredenominatedorlinkedTable" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r40" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesdilutedTable", "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClosingForeignExchangeRate": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } }, "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Exchange rate" } } }, "localname": "ClosingForeignExchangeRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofexchangerateoftheUSdollarinrelationtotheNISTable" ], "xbrltype": "decimalItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable", "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_ComputerEquipmentMember": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Computer equipment [member]", "terseLabel": "Computers [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis": { "auth_ref": [ "r106" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Continuing involvement in derecognised financial assets by type of instrument [axis]" } } }, "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable", "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable", "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r15", "r80", "r81" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentInvestments": { "auth_ref": [ "r14" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current investments." } }, "en-us": { "role": { "label": "Current investments", "terseLabel": "Marketable securities" } } }, "localname": "CurrentInvestments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleoffinancialinstrumentsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Current prepaid expenses", "totalLabel": "Total" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationExpense": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation expense", "terseLabel": "Depreciation" } } }, "localname": "DepreciationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for earnings per share." } }, "en-us": { "role": { "label": "Description of accounting policy for earnings per share [text block]", "terseLabel": "Earning per share" } } }, "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Employee benefits" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Description of accounting policy for financial assets [text block]", "terseLabel": "Investments and other financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for foreign currency translation." } }, "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Translation of balances and transactions in foreign currency" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Description of accounting policy for impairment of non-financial assets [text block]", "terseLabel": "Impairment of non-financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } }, "en-us": { "role": { "label": "Description of accounting policy for intangible assets and goodwill [text block]", "terseLabel": "Intangible assets" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Description of accounting policy for issued capital [text block]", "terseLabel": "Share capital" } } }, "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based payment" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Description of accounting policy for trade and other payables [text block]", "terseLabel": "Trade payables" } } }, "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for warrants. Warrants are financial instruments that give the holder the right to purchase ordinary shares." } }, "en-us": { "role": { "label": "Description of accounting policy for warrants [text block]", "terseLabel": "Issuance of units comprised of warrants and ordinary shares" } } }, "localname": "DescriptionOfAccountingPolicyForWarrantsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "auth_ref": [ "r73" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable", "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free interest rate", "verboseLabel": "Risk-free interest" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable", "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "percentItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r55", "r56" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share (in U.S. dollars): (in Dollars per share)" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options." } }, "en-us": { "role": { "label": "Dilutive effect of share options on number of ordinary shares", "terseLabel": "Options" } } }, "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_DirectorsRemunerationExpense": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of remuneration paid or payable to the entity's directors." } }, "en-us": { "role": { "label": "Directors' remuneration expense", "terseLabel": "Directors\u2019 fees" } } }, "localname": "DirectorsRemunerationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/CriticalAccountingEstimatesandJudgments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory": { "auth_ref": [ "r47" ], "lang": { "en": { "role": { "documentation": "The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]" } }, "en-us": { "role": { "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]", "terseLabel": "Schedule of compensation to key management personnel for employee services" } } }, "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "CASH AND CASH EQUIVALENTS" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/CashandCashEquivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments." } }, "en-us": { "role": { "label": "Disclosure of commitments [text block]", "terseLabel": "COMMITMENTS" } } }, "localname": "DisclosureOfCommitmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r100", "r102", "r105" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial instruments" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r40" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of depreciation of property and equipment" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "EARNINGS (LOSS) PER SHARE" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "auth_ref": [ "r44" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for employee benefits." } }, "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "EMPLOYEE BENEFIT LIABILITIES" } } }, "localname": "DisclosureOfEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/EmployeeBenefitLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]", "terseLabel": "FINANCE INCOME (EXPENSES), NET" } } }, "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/FinanceIncomeExpensesNet" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]" } }, "en-us": { "role": { "label": "Disclosure of general and administrative expense [text block]", "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES" } } }, "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/GeneralandAdministrativeExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory": { "auth_ref": [ "r107" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for general hedge accounting." } }, "en-us": { "role": { "label": "Disclosure of general hedge accounting [text block]", "terseLabel": "GENERAL" } } }, "localname": "DisclosureOfGeneralHedgeAccountingExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/General" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r38" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "TAXES ON INCOME" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TaxesonIncome" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for intangible assets." } }, "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "INTANGIBLE ASSETS" } } }, "localname": "DisclosureOfIntangibleAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]" } } }, "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedParties" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Disclosure of research and development expense [text block]", "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSES" } } }, "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ResearchandDevelopmentExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r94" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "SHARE-BASED PAYMENT" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareBasedPayment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r69", "r70" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Gains (losses) from exchange rate differences on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r1", "r2", "r30" ], "calculation": { "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits expense", "totalLabel": "Total" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r48" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails", "http://xtlb.com/role/ScheduleofoutstandingoptionsTable", "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r14", "r18", "r76", "r78", "r85", "r86", "r88" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet", "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r14" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected dividend as percentage, share options granted", "terseLabel": "Dividend yield" } } }, "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable", "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "percentItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "terseLabel": "Expenses relating to options and shares to employees and non-employees" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FeeAndCommissionExpense": { "auth_ref": [ "r28" ], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": 2.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } }, "en-us": { "role": { "label": "Fee and commission expense", "terseLabel": "Bank account management fees and commissions" } } }, "localname": "FeeAndCommissionExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r26" ], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": 2.0, "parentTag": "xtlb_FinanceIncomeexpensesNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "totalLabel": "Total finance expenses" } } }, "localname": "FinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r28" ], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": 1.0, "parentTag": "xtlb_FinanceIncomeexpensesNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "totalLabel": "Total finance income" } } }, "localname": "FinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncomeCost": { "auth_ref": [ "r28" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "xtlb_ComprehensiveIncomelossForTheYeardiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income (cost)", "totalLabel": "Finance income (expenses), net" } } }, "localname": "FinanceIncomeCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAvailableforsale": { "auth_ref": [ "r115" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-derivative financial assets that are designated as available for sale or are not classified as (a) loans and receivables; (b) held-to-maturity investments; or (c) financial assets at fair value through profit or loss. [Refer: Derivative financial assets; Financial assets at fair value through profit or loss; Held-to-maturity investments]" } }, "en-us": { "role": { "label": "Financial assets available-for-sale", "terseLabel": "Fair value opening balance" } } }, "localname": "FinancialAssetsAvailableforsale", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofchangesinmarketablesecuritiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilities": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Financial liabilities", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning" } } }, "localname": "FinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r27", "r35", "r36", "r37", "r53", "r84", "r108" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "terseLabel": "Tax benefit" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofreconciliationbetweenthetheoreticaltaxexpenseTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "auth_ref": [ "r72" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Increase (decrease) in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } }, "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Exercise of warrants to ordinary shares" } } }, "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payment to employees and non-employees" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted": { "auth_ref": [ "r98" ], "lang": { "en": { "role": { "documentation": "Information about how the expected volatility used for pricing share options granted was determined, including an explanation of the extent to which expected volatility was based on historical volatility." } }, "en-us": { "role": { "label": "Information about how expected volatility was determined, share options granted", "terseLabel": "Expected volatility, description" } } }, "localname": "InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_InsuranceExpense": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from purchased insurance." } }, "en-us": { "role": { "label": "Insurance expense", "terseLabel": "Insurance" } } }, "localname": "InsuranceExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r11", "r59" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestIncomeOnDeposits": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of interest income on deposits. [Refer: Interest income]" } }, "en-us": { "role": { "label": "Interest income on deposits", "terseLabel": "Interest income on bank deposits" } } }, "localname": "InterestIncomeOnDeposits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } }, "en-us": { "role": { "label": "Interest received, classified as investing activities", "terseLabel": "Interest from bank deposit" } } }, "localname": "InterestReceivedClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentIncome": { "auth_ref": [ "r28", "r51" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of investment income, such as interest and dividends." } }, "en-us": { "role": { "label": "Investment income", "terseLabel": "Receipt of investment" } } }, "localname": "InvestmentIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r18" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital - ordinary shares of NIS 0.1 par value: Authorized - December 31, 2021 and 2020 - 1,450,000,000; Issued and outstanding - December 31, 2021 - 544,906,149. December 31, 2020 - 514,205,799" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Share capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r45" ], "calculation": { "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable": { "order": 2.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, post-employment benefits", "terseLabel": "Pension, post retirement and other benefits" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LoansReceived": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of loans received." } }, "en-us": { "role": { "label": "Loans received", "terseLabel": "Received amount" } } }, "localname": "LoansReceived", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Major ordinary share transactions [member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "MajorOrdinaryShareTransactionsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r15", "r80", "r82" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "NON-CURRENT ASSETS:" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "NON-CURRENT LIABILITIES:" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NumberOfEmployees": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } }, "en-us": { "role": { "label": "Number of employees", "terseLabel": "Number of persons" } } }, "localname": "NumberOfEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r20" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Ordinary shares, authorized" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Ordinary shares, issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r22" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "terseLabel": "Ordinary shares, outstanding" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r23", "r55" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary shares [member]", "terseLabel": "Ordinary Shares [Member]" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income attributable to non-controlling interests. [Refer: Non-controlling interests; Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, attributable to non-controlling interests", "terseLabel": "Total comprehensive income (loss) for the year" } } }, "localname": "OtherComprehensiveIncomeAttributableToNoncontrollingInterests", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofprofitlossattributedtoordinaryshareholdersbasicTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeBeforeTax": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, before tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, before tax", "terseLabel": "Total comprehensive income (loss) for the year (basic)" } } }, "localname": "OtherComprehensiveIncomeBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofprofitlossattributedtoordinaryshareholdersdilutedTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentPayables": { "auth_ref": [ "r14" ], "calculation": { "http://xtlb.com/role/ScheduleofcompositionofaccountspayableTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other accounts payable", "totalLabel": "Total accounts payable" } } }, "localname": "OtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcarryingamountofotheraccountspayableTable", "http://xtlb.com/role/ScheduleofcompositionofaccountspayableTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r17" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "OtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherExpenseByNature": { "auth_ref": [ "r1", "r30" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Other expenses, by nature", "terseLabel": "Other" } } }, "localname": "OtherExpenseByNature", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinanceCost": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } }, "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other finance expenses" } } }, "localname": "OtherFinanceCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinanceIncome": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]" } }, "en-us": { "role": { "label": "Other finance income", "terseLabel": "Other finance income" } } }, "localname": "OtherFinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentFinancialAssets": { "auth_ref": [ "r12" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]" } }, "en-us": { "role": { "label": "Other non-current financial assets", "terseLabel": "Fixed assets, net" } } }, "localname": "OtherNoncurrentFinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReserves": { "auth_ref": [ "r18" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves", "terseLabel": "Reserve from transactions with non-controlling interests" } } }, "localname": "OtherReserves", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReservesMember": { "auth_ref": [ "r6", "r24" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves [member]", "terseLabel": "Reserve from transactions with non-controlling interests", "verboseLabel": "Reserve from transactions with non- controlling interests" } } }, "localname": "OtherReservesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)", "terseLabel": "Temporary differences in the reported year for which no deferred taxes were recognized" } } }, "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofreconciliationbetweenthetheoreticaltaxexpenseTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "terseLabel": "Ordinary shares, par value (in New Shekels per share)" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } }, "en-us": { "role": { "label": "Post-employment benefit expense, defined contribution plans", "terseLabel": "Defined contribution plans for employees" } } }, "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/EmployeeBenefitLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfOptions": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of options." } }, "en-us": { "role": { "label": "Proceeds from exercise of options", "terseLabel": "Exercise of warrants" } } }, "localname": "ProceedsFromExerciseOfOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "auth_ref": [ "r64" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } }, "en-us": { "role": { "label": "Proceeds from exercise of warrants", "terseLabel": "Exercise of warrants" } } }, "localname": "ProceedsFromExerciseOfWarrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfessionalFeesExpense": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } }, "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Professional services" } } }, "localname": "ProfessionalFeesExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r3", "r25", "r65", "r77", "r79", "r80", "r109", "r110", "r112", "r114" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Income (Loss) for the year", "verboseLabel": "Income (loss) for the year" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow", "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r28", "r54" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "xtlb_ComprehensiveIncomelossForTheYeardiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating loss" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r89", "r90", "r91", "r95", "r105", "r113" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsDetails", "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable", "http://xtlb.com/role/ScheduleofwarrantexercisesTable", "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r89", "r90", "r91", "r95", "r105", "r113" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsDetails", "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable", "http://xtlb.com/role/ScheduleofwarrantexercisesTable", "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "auth_ref": [ "r95" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [axis]" } } }, "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": { "auth_ref": [ "r95" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]" } }, "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [member]" } } }, "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_ReceivablesFromContractsWithCustomers": { "auth_ref": [ "r92", "r93" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due." } }, "en-us": { "role": { "label": "Receivables from contracts with customers", "terseLabel": "Required payment of liquidated damages" } } }, "localname": "ReceivablesFromContractsWithCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r60" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r18", "r31" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_RoyaltyExpense": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from royalties." } }, "en-us": { "role": { "label": "Royalty expense", "terseLabel": "Royalty payment" } } }, "localname": "RoyaltyExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SettlementsFairValueMeasurementLiabilities": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease in the fair value measurement of liabilities resulting from settlements. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Settlements, fair value measurement, liabilities", "negatedLabel": "Revaluation during the year" } } }, "localname": "SettlementsFairValueMeasurementLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Bank deposits with original maturities of three months or less" } } }, "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxEffectFromChangeInTaxRate": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect from change in tax rate", "terseLabel": "Increase (decrease) in taxes resulting mainly from exchange rate differentials and taxable losses in the reported year for which no deferred taxes were recognized" } } }, "localname": "TaxEffectFromChangeInTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofreconciliationbetweenthetheoreticaltaxexpenseTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfImpairmentOfGoodwill": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount representing the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to impairment of goodwill. [Refer: Accounting profit; Goodwill]" } }, "en-us": { "role": { "label": "Tax effect of impairment of goodwill", "terseLabel": "Carryforward tax losses" } } }, "localname": "TaxEffectOfImpairmentOfGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfTaxLosses": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect of tax losses", "terseLabel": "Theoretical tax expense (benefit)" } } }, "localname": "TaxEffectOfTaxLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofreconciliationbetweenthetheoreticaltaxexpenseTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r89", "r90", "r91", "r95", "r105", "r113" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Top of range [member]" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsDetails", "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable", "http://xtlb.com/role/ScheduleofwarrantexercisesTable", "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "auth_ref": [ "r16", "r19" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } }, "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Accounts payable" } } }, "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "auth_ref": [ "r19" ], "calculation": { "http://xtlb.com/role/ScheduleofcompositionofaccountspayableTable": { "order": 1.0, "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } }, "en-us": { "role": { "label": "Trade payables", "terseLabel": "Trade payables" } } }, "localname": "TradeAndOtherPayablesToTradeSuppliers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompositionofaccountspayableTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TravelExpense": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from travel." } }, "en-us": { "role": { "label": "Travel expense", "terseLabel": "Investor relations and travel" } } }, "localname": "TravelExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfInstrumentMember": { "auth_ref": [ "r106" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of instrument' axis if no other member is used." } }, "en-us": { "role": { "label": "Types of instrument [member]" } } }, "localname": "TypesOfInstrumentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable", "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r96" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable" ], "xbrltype": "stringItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages and salaries", "terseLabel": "Salaries and expenses relating to employees and service providers" } } }, "localname": "WagesAndSalaries", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average duration of defined benefit obligation", "terseLabel": "Weighted-average term" } } }, "localname": "WeightedAverageDurationOfDefinedBenefitObligation2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r95" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Contractual term life (in years)", "verboseLabel": "Expected life (years)" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable", "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of issued ordinary shares (in Shares)" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "xtlb_ADSIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ADSIssued", "terseLabel": "ADS's issued" } } }, "localname": "ADSIssued", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "xtlb_AccountsPayableDetailsScheduleofcarryingamountofotheraccountspayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable (Details) - Schedule of carrying amount of other accounts payable [Line Items]" } } }, "localname": "AccountsPayableDetailsScheduleofcarryingamountofotheraccountspayableLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcarryingamountofotheraccountspayableTable" ], "xbrltype": "stringItemType" }, "xtlb_AccountsPayableDetailsScheduleofcarryingamountofotheraccountspayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable (Details) - Schedule of carrying amount of other accounts payable [Table]" } } }, "localname": "AccountsPayableDetailsScheduleofcarryingamountofotheraccountspayableTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcarryingamountofotheraccountspayableTable" ], "xbrltype": "stringItemType" }, "xtlb_AccountsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable [Abstract]" } } }, "localname": "AccountsPayableLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/AccountsPayable" ], "xbrltype": "stringItemType" }, "xtlb_AccountsPayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable [Table]" } } }, "localname": "AccountsPayableTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/AccountsPayable" ], "xbrltype": "stringItemType" }, "xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities.", "label": "AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities (a)" } } }, "localname": "AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_AmericanDepositorySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AmericanDepositorySharesMember", "terseLabel": "American Depository Shares [Member]" } } }, "localname": "AmericanDepositorySharesMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "xtlb_AnnualGeneralMeetingOfShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AnnualGeneralMeetingOfShareholdersMember", "terseLabel": "Annual General Meeting of Shareholders [Member]" } } }, "localname": "AnnualGeneralMeetingOfShareholdersMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "domainItemType" }, "xtlb_AssetsRemainedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assets remained amount.", "label": "AssetsRemainedAmount", "terseLabel": "Assets remained amount" } } }, "localname": "AssetsRemainedAmount", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_BNonCashActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BNonCashActivitiesAbstract", "terseLabel": "(b) Non-cash activities:" } } }, "localname": "BNonCashActivitiesAbstract", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "xtlb_BlackScholesMertonOptionsPricingModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BlackScholesMertonOptionsPricingModelMember", "terseLabel": "Black-Scholes-Merton Options pricing model [Member]" } } }, "localname": "BlackScholesMertonOptionsPricingModelMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable" ], "xbrltype": "domainItemType" }, "xtlb_CanndocLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CanndocLtdMember", "terseLabel": "Canndoc Ltd [Member]" } } }, "localname": "CanndocLtdMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "xtlb_CashAndCashEquivalent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]", "label": "CashAndCashEquivalent", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalent", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcashandcashequivalentsTable", "http://xtlb.com/role/ScheduleofcashandcashequivalentsaredenominatedorlinkedTable" ], "xbrltype": "monetaryItemType" }, "xtlb_CashFlowsFromFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashFlowsFromFinancingActivitiesAbstract", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "CashFlowsFromFinancingActivitiesAbstract", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "xtlb_CashandCashEquivalentsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents (Details) [Line Items]" } } }, "localname": "CashandCashEquivalentsDetailsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "xtlb_CashandCashEquivalentsDetailsScheduleofcashandcashequivalentsaredenominatedorlinkedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents are denominated or linked [Line Items]" } } }, "localname": "CashandCashEquivalentsDetailsScheduleofcashandcashequivalentsaredenominatedorlinkedLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcashandcashequivalentsaredenominatedorlinkedTable" ], "xbrltype": "stringItemType" }, "xtlb_CashandCashEquivalentsDetailsScheduleofcashandcashequivalentsaredenominatedorlinkedTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents are denominated or linked [Table]" } } }, "localname": "CashandCashEquivalentsDetailsScheduleofcashandcashequivalentsaredenominatedorlinkedTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcashandcashequivalentsaredenominatedorlinkedTable" ], "xbrltype": "stringItemType" }, "xtlb_CashandCashEquivalentsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents (Details) [Table]" } } }, "localname": "CashandCashEquivalentsDetailsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "xtlb_CashandCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [Abstract]" } } }, "localname": "CashandCashEquivalentsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CashandCashEquivalents" ], "xbrltype": "stringItemType" }, "xtlb_CashandCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Table]" } } }, "localname": "CashandCashEquivalentsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CashandCashEquivalents" ], "xbrltype": "stringItemType" }, "xtlb_ChairmanOfBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ChairmanOfBoardMember", "terseLabel": "Chairman of Board [Member]" } } }, "localname": "ChairmanOfBoardMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_ChiefExecutiveOfficerNewMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ChiefExecutiveOfficerNewMember", "terseLabel": "Chief Executive Officer (new) [Member]" } } }, "localname": "ChiefExecutiveOfficerNewMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_Commitments": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments", "terseLabel": "Commitments" } } }, "localname": "Commitments", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "xtlb_ComprehensiveIncomelossForTheYearbasic": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total comprehensive income (loss) for the year (basic).", "label": "ComprehensiveIncomelossForTheYearbasic", "totalLabel": "Total comprehensive income (loss) for the year (basic)" } } }, "localname": "ComprehensiveIncomelossForTheYearbasic", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "xtlb_ComprehensiveIncomelossForTheYeardiluted": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total comprehensive income (loss) for the year (diluted).", "label": "ComprehensiveIncomelossForTheYeardiluted", "totalLabel": "Total comprehensive income (loss) for the year (diluted)" } } }, "localname": "ComprehensiveIncomelossForTheYeardiluted", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "xtlb_ConsolidatedStatementsOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Changes in Equity [Abstract]" } } }, "localname": "ConsolidatedStatementsOfChangesInEquityAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_CreationsDateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CreationsDateAxis", "terseLabel": "Creations Date [Axis]" } } }, "localname": "CreationsDateAxis", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "stringItemType" }, "xtlb_CreationsDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CreationsDate [Domain]" } } }, "localname": "CreationsDateDomain", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_CriticalAccountingEstimatesandJudgmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Critical Accounting Estimates and Judgments [Abstract]" } } }, "localname": "CriticalAccountingEstimatesandJudgmentsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CriticalAccountingEstimatesandJudgments" ], "xbrltype": "stringItemType" }, "xtlb_CriticalAccountingEstimatesandJudgmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Critical Accounting Estimates and Judgments [Table]" } } }, "localname": "CriticalAccountingEstimatesandJudgmentsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CriticalAccountingEstimatesandJudgments" ], "xbrltype": "stringItemType" }, "xtlb_CurrentMarketableSecuritie": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.", "label": "CurrentMarketableSecuritie", "terseLabel": "Balances of shares total" } } }, "localname": "CurrentMarketableSecuritie", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_CurrentMarketableSecurities": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.", "label": "CurrentMarketableSecurities", "terseLabel": "Marketable securities \u2013 InterCure Ltd", "verboseLabel": "Total marketable securities" } } }, "localname": "CurrentMarketableSecurities", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet", "http://xtlb.com/role/ScheduleofchangesinmarketablesecuritiesTable" ], "xbrltype": "monetaryItemType" }, "xtlb_CurrentPrepaidExpensesOther": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": { "order": 2.0, "parentTag": "ifrs-full_CurrentPrepaidExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current prepaid expenses other.", "label": "CurrentPrepaidExpensesOther", "terseLabel": "Prepaid expenses" } } }, "localname": "CurrentPrepaidExpensesOther", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "xtlb_DateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DateAxis", "terseLabel": "Date Axis" } } }, "localname": "DateAxis", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable", "http://xtlb.com/role/ScheduleofwarrantexercisesTable", "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "stringItemType" }, "xtlb_DateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Date [Domain]" } } }, "localname": "DateDomain", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable", "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "domainItemType" }, "xtlb_DepositaryShareAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DepositaryShareAxis", "terseLabel": "Depositary Share [Axis]" } } }, "localname": "DepositaryShareAxis", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "xtlb_DepositaryShareDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DepositaryShare [Domain]" } } }, "localname": "DepositaryShareDomain", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "xtlb_DepositsWithMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deposits with maturity", "label": "DepositsWithMaturity", "terseLabel": "Maturity period" } } }, "localname": "DepositsWithMaturity", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsDetails" ], "xbrltype": "durationItemType" }, "xtlb_DescriptionOfAccountingPolicyForBasisOfPresentationOfFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy basis of presentation of the financial statements.", "label": "DescriptionOfAccountingPolicyForBasisOfPresentationOfFinancialStatementsPolicyTextBlock", "terseLabel": "Basis of presentation of the consolidated financial statements" } } }, "localname": "DescriptionOfAccountingPolicyForBasisOfPresentationOfFinancialStatementsPolicyTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "xtlb_DescriptionOfAccountingPolicyForConsolidatedFinancialStatementsExplanatoryPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for consolidated financial statements.", "label": "DescriptionOfAccountingPolicyForConsolidatedFinancialStatementsExplanatoryPolicyTextBlock", "terseLabel": "Consolidated financial statements" } } }, "localname": "DescriptionOfAccountingPolicyForConsolidatedFinancialStatementsExplanatoryPolicyTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "xtlb_DescriptionOfForeignCurrencyExchangeRateRisk": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the foreign currency exchange rate risk.", "label": "DescriptionOfForeignCurrencyExchangeRateRisk", "terseLabel": "Description of foreign currency exchange rate risk" } } }, "localname": "DescriptionOfForeignCurrencyExchangeRateRisk", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails" ], "xbrltype": "stringItemType" }, "xtlb_DescriptionOfWarrantsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of warrants shall be exercisable.", "label": "DescriptionOfWarrantsExercisable", "terseLabel": "Description of warrants exercisable" } } }, "localname": "DescriptionOfWarrantsExercisable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "xtlb_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block] [Abstract]" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfCashAndCashEquivalentsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block] [Abstract]" } } }, "localname": "DisclosureOfCashAndCashEquivalentsTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfChangesInFinancialLiabilitiesFromFinanceActivitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of changes in financial liabilities from finance activities.", "label": "DisclosureOfChangesInFinancialLiabilitiesFromFinanceActivitiesTextBlock", "terseLabel": "Schedule of changes in financial liabilities from finance activities" } } }, "localname": "DisclosureOfChangesInFinancialLiabilitiesFromFinanceActivitiesTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfCommitmentsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments [Abstract]" } } }, "localname": "DisclosureOfCommitmentsTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about cash and cash equivalents.", "label": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock", "terseLabel": "Schedule of cash and cash equivalents" } } }, "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about currencies in which the cash and cash equivalents are denominated.", "label": "DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock", "terseLabel": "Schedule of cash and cash equivalents are denominated or linked" } } }, "localname": "DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CashandCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutExchangeRateExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information aboutexchange rate.", "label": "DisclosureOfDetailedInformationAboutExchangeRateExplanatoryTableTextBlock", "terseLabel": "Schedule of exchange rate of the U.S. dollar in relation to the NIS" } } }, "localname": "DisclosureOfDetailedInformationAboutExchangeRateExplanatoryTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about the exercise price and the remaining contractual life for options outstanding.", "label": "DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock", "terseLabel": "Schedule of exercise price and the remaining contractual life (in years)" } } }, "localname": "DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutFairValueOptionsGrantedForWeightedAverageAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureOfDetailedInformationAboutFairValueOptionsGrantedForWeightedAverageAssumptionsTableTextBlock", "terseLabel": "Schedule of detailed information about the fair value for options granted" } } }, "localname": "DisclosureOfDetailedInformationAboutFairValueOptionsGrantedForWeightedAverageAssumptionsTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about general and administrative expenses.", "label": "DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesTableTextBlock", "terseLabel": "Schedule of general and administrative expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/GeneralandAdministrativeExpensesTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about changes in marketable securities.", "label": "DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock", "terseLabel": "Schedule of changes in marketable securities" } } }, "localname": "DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about the number and weighted average exercise prices of share options.", "label": "DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock", "terseLabel": "Schedule of number of share options and their related weighted average exercise prices" } } }, "localname": "DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about the outstanding options.", "label": "DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock", "terseLabel": "Schedule of outstanding options" } } }, "localname": "DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about prepaid expenses.", "label": "DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "terseLabel": "Schedule of prepaid expenses and othe current assets" } } }, "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/PrepaidExpensesandOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about research and development expenses.", "label": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock", "terseLabel": "Schedule of research and development expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ResearchandDevelopmentExpensesTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfEarningsPerShareTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of earnings per share [text block] [Abstract]" } } }, "localname": "DisclosureOfEarningsPerShareTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfEmployeeBenefitsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of employee benefits [text block] [Abstract]" } } }, "localname": "DisclosureOfEmployeeBenefitsTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfFinanceIncomeCostTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Income (Expenses), Net [Abstract]" } } }, "localname": "DisclosureOfFinanceIncomeCostTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments and Financial Risk Management [Abstract]" } } }, "localname": "DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatoryAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of the entity's financial instruments and financial risk management.", "label": "DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatoryTextBlock", "terseLabel": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT" } } }, "localname": "DisclosureOfFinancialInstrumentsAndFinancialRiskManagementExplanatoryTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of general and administrative expense [text block] [Abstract]" } } }, "localname": "DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfGeneralHedgeAccountingTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of general hedge accounting [text block] [Abstract]" } } }, "localname": "DisclosureOfGeneralHedgeAccountingTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfIncomeTaxTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of income tax [text block] [Abstract]" } } }, "localname": "DisclosureOfIncomeTaxTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfIntangibleAssetsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets [text block] [Abstract]" } } }, "localname": "DisclosureOfIntangibleAssetsTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfMarketableSecuritiesExplanatoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Marketable Securities Explanatory [Abstract]" } } }, "localname": "DisclosureOfMarketableSecuritiesExplanatoryAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfMarketableSecuritiesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for marketable securities.", "label": "DisclosureOfMarketableSecuritiesExplanatoryTextBlock", "terseLabel": "MARKETABLE SECURITIES \u2013 InterCure Ltd" } } }, "localname": "DisclosureOfMarketableSecuritiesExplanatoryTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtd" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfOtherAccountsPayablesExplanatoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Other Accounts Payables Explanatory [Abstract]" } } }, "localname": "DisclosureOfOtherAccountsPayablesExplanatoryAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfOtherAccountsPayablesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other accounts payables Explanatory.", "label": "DisclosureOfOtherAccountsPayablesExplanatoryTextBlock", "terseLabel": "ACCOUNTS PAYABLE" } } }, "localname": "DisclosureOfOtherAccountsPayablesExplanatoryTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/AccountsPayable" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfPrepaidExpensesExplanatoryTableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Prepaid Expenses Explanatory Table [Abstract]" } } }, "localname": "DisclosureOfPrepaidExpensesExplanatoryTableAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfPrepaidExpensesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of prepaid expenses explanatory.", "label": "DisclosureOfPrepaidExpensesExplanatoryTableTextBlock", "terseLabel": "PREPAID EXPENSES AND OTHE CURRENT ASSETS" } } }, "localname": "DisclosureOfPrepaidExpensesExplanatoryTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/PrepaidExpensesandOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfRelatedPartyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of related party [text block] [Abstract]" } } }, "localname": "DisclosureOfRelatedPartyTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of research and development expense [text block] [Abstract]" } } }, "localname": "DisclosureOfResearchAndDevelopmentExpenseTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block] [Abstract]" } } }, "localname": "DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_EachWarrantIsExercisableToShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Each warrant is exercisable to shares.", "label": "EachWarrantIsExercisableToShares", "terseLabel": "Each warrant is exercisable to shares" } } }, "localname": "EachWarrantIsExercisableToShares", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "xtlb_EarningsLossPerShareDetailsScheduleofweightedaveragenumberofordinarysharesbasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings (Loss) Per Share (Details) - Schedule of weighted-average number of ordinary shares (basic) [Line Items]" } } }, "localname": "EarningsLossPerShareDetailsScheduleofweightedaveragenumberofordinarysharesbasicLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "stringItemType" }, "xtlb_EarningsLossPerShareDetailsScheduleofweightedaveragenumberofordinarysharesbasicTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings (Loss) Per Share (Details) - Schedule of weighted-average number of ordinary shares (basic) [Table]" } } }, "localname": "EarningsLossPerShareDetailsScheduleofweightedaveragenumberofordinarysharesbasicTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "stringItemType" }, "xtlb_EarningsLossPerShareDetailsScheduleofweightedaveragenumberofordinarysharesdilutedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings (Loss) Per Share (Details) - Schedule of weighted-average number of ordinary shares (diluted) [Line Items]" } } }, "localname": "EarningsLossPerShareDetailsScheduleofweightedaveragenumberofordinarysharesdilutedLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesdilutedTable" ], "xbrltype": "stringItemType" }, "xtlb_EarningsLossPerShareDetailsScheduleofweightedaveragenumberofordinarysharesdilutedTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings (Loss) Per Share (Details) - Schedule of weighted-average number of ordinary shares (diluted) [Table]" } } }, "localname": "EarningsLossPerShareDetailsScheduleofweightedaveragenumberofordinarysharesdilutedTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesdilutedTable" ], "xbrltype": "stringItemType" }, "xtlb_EffectOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effect of warrants.", "label": "EffectOfWarrants", "terseLabel": "Effect of warrants" } } }, "localname": "EffectOfWarrants", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesdilutedTable" ], "xbrltype": "sharesItemType" }, "xtlb_EmployeeBenefitLiabilitiesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of employee benefits [Abstract]" } } }, "localname": "EmployeeBenefitLiabilitiesDetailsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EmployeeBenefitLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "xtlb_EmployeeBenefitLiabilitiesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefit Liabilities (Details) [Table]" } } }, "localname": "EmployeeBenefitLiabilitiesDetailsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EmployeeBenefitLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "xtlb_EmployeeBenefitLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefit Liabilities [Abstract]" } } }, "localname": "EmployeeBenefitLiabilitiesLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EmployeeBenefitLiabilities" ], "xbrltype": "stringItemType" }, "xtlb_EmployeeBenefitLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefit Liabilities [Table]" } } }, "localname": "EmployeeBenefitLiabilitiesTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EmployeeBenefitLiabilities" ], "xbrltype": "stringItemType" }, "xtlb_ExercisePriceInUSDperWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share.", "label": "ExercisePriceInUSDperWarrant", "terseLabel": "Exercise price in USD (per warrant)" } } }, "localname": "ExercisePriceInUSDperWarrant", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable" ], "xbrltype": "perShareItemType" }, "xtlb_ExercisePriceOfShareOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The exercise price of outstanding share options.", "label": "ExercisePriceOfShareOptionsOutstanding", "terseLabel": "Range of exercise prices" } } }, "localname": "ExercisePriceOfShareOptionsOutstanding", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable" ], "xbrltype": "perShareItemType" }, "xtlb_ExercisesDuringTheYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercises during the year.", "label": "ExercisesDuringTheYear", "negatedLabel": "Exercises during the year" } } }, "localname": "ExercisesDuringTheYear", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable" ], "xbrltype": "monetaryItemType" }, "xtlb_ExpirTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expir term.", "label": "ExpirTerm", "terseLabel": "Expiry term" } } }, "localname": "ExpirTerm", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "xtlb_ExpirationDateWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date.", "label": "ExpirationDateWarrants", "terseLabel": "Expiration date" } } }, "localname": "ExpirationDateWarrants", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_FebruarySeventeenTwoThousandSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FebruarySeventeenTwoThousandSeventeenMember", "terseLabel": "February 17, 2017 [Member]" } } }, "localname": "FebruarySeventeenTwoThousandSeventeenMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable", "http://xtlb.com/role/ScheduleofwarrantexercisesTable" ], "xbrltype": "domainItemType" }, "xtlb_FeesRelatedToServiceProviders": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fees related to service providers.", "label": "FeesRelatedToServiceProviders", "terseLabel": "Research and development expense" } } }, "localname": "FeesRelatedToServiceProviders", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofresearchanddevelopmentexpensesTable" ], "xbrltype": "monetaryItemType" }, "xtlb_FinanceExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FinanceExpensesAbstract", "terseLabel": "Finance expenses:" } } }, "localname": "FinanceExpensesAbstract", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "stringItemType" }, "xtlb_FinanceExpensesRevaluationOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": 3.0, "parentTag": "ifrs-full_FinanceCosts", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance expenses revaluation of marketable securities.", "label": "FinanceExpensesRevaluationOfMarketableSecurities", "negatedLabel": "Revaluation of marketable securities" } } }, "localname": "FinanceExpensesRevaluationOfMarketableSecurities", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "xtlb_FinanceIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FinanceIncomeAbstract", "terseLabel": "Finance income:" } } }, "localname": "FinanceIncomeAbstract", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "stringItemType" }, "xtlb_FinanceIncomeAndFinanceCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance income and finance costs.", "label": "FinanceIncomeAndFinanceCosts", "terseLabel": "Finance income and finance costs" } } }, "localname": "FinanceIncomeAndFinanceCosts", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "xtlb_FinanceIncomeexpensesNet": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity.", "label": "FinanceIncomeexpensesNet", "totalLabel": "Finance income (expenses), net" } } }, "localname": "FinanceIncomeexpensesNet", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments and Financial Risk Management (Details) - Schedule of changes in financial liabilities from finance activities [Line Items]" } } }, "localname": "FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable" ], "xbrltype": "stringItemType" }, "xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments and Financial Risk Management (Details) - Schedule of changes in financial liabilities from finance activities [Table]" } } }, "localname": "FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable" ], "xbrltype": "stringItemType" }, "xtlb_ForeignCurrenciesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ForeignCurrenciesMember", "terseLabel": "U.S. dollars [Member]" } } }, "localname": "ForeignCurrenciesMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcashandcashequivalentsaredenominatedorlinkedTable" ], "xbrltype": "domainItemType" }, "xtlb_FourDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FourDirectorsMember", "terseLabel": "Four Directors [Member]" } } }, "localname": "FourDirectorsMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": 4.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gain recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax.", "label": "GainOnExchangeDifferencesOnTranslationNetOfTax", "terseLabel": "Exchange differences" } } }, "localname": "GainOnExchangeDifferencesOnTranslationNetOfTax", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "xtlb_GainsFromExchangeRateDifferencesOnCashAndCashEquivalents": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains from exchange rate differences on cash and cash equivalents.", "label": "GainsFromExchangeRateDifferencesOnCashAndCashEquivalents", "negatedLabel": "Losses (gains) from exchange rate differences on cash and cash equivalents" } } }, "localname": "GainsFromExchangeRateDifferencesOnCashAndCashEquivalents", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_GainsLossesOnFairValueOnMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The gains (losses) arising from changes in fair value marketable securities.", "label": "GainsLossesOnFairValueOnMarketableSecurities", "terseLabel": "Changes in fair value during the year" } } }, "localname": "GainsLossesOnFairValueOnMarketableSecurities", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofchangesinmarketablesecuritiesTable" ], "xbrltype": "monetaryItemType" }, "xtlb_GeneralAndAdministrativeExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "General and administrative expenses.", "label": "GeneralAndAdministrativeExpenses", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpenses", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "xtlb_GeneralLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "localname": "GeneralLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/General" ], "xbrltype": "stringItemType" }, "xtlb_GeneralTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General [Table]" } } }, "localname": "GeneralTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/General" ], "xbrltype": "stringItemType" }, "xtlb_GovernmentAuthorities": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": { "order": 1.0, "parentTag": "ifrs-full_CurrentPrepaidExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "GovernmentAuthorities", "terseLabel": "Government authorities" } } }, "localname": "GovernmentAuthorities", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "xtlb_GrandDateIssuedEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GrandDateIssuedEightMember", "terseLabel": "March 31, 2016 [Member]" } } }, "localname": "GrandDateIssuedEightMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_GrandDateIssuedFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GrandDateIssuedFiveMember", "terseLabel": "March 25, 2015 [Member]" } } }, "localname": "GrandDateIssuedFiveMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_GrandsDateIssuedElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GrandsDateIssuedElevenMember", "terseLabel": "July 7, 2020 [Member]" } } }, "localname": "GrandsDateIssuedElevenMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_GrandsDateIssuedThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grands Date Issued Three [Member]", "label": "GrandsDateIssuedThreeMember", "terseLabel": "December 30, 2014" } } }, "localname": "GrandsDateIssuedThreeMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_GrossFundRaised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gross fund raised.", "label": "GrossFundRaised", "terseLabel": "Gross funds raised" } } }, "localname": "GrossFundRaised", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract", "terseLabel": "Income and expenses not involving operating cash flows:" } } }, "localname": "IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "xtlb_IncreaseOfReserveDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description related to reserve.", "label": "IncreaseOfReserveDescription", "terseLabel": "Increase of reserve, description" } } }, "localname": "IncreaseOfReserveDescription", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "stringItemType" }, "xtlb_IncreasingCapitalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increasing capital amount.", "label": "IncreasingCapitalAmount", "terseLabel": "Raising capital" } } }, "localname": "IncreasingCapitalAmount", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_IntangibleAssetOtherInformationMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IntangibleAssetOtherInformationMaturityDate", "terseLabel": "Expires term, description" } } }, "localname": "IntangibleAssetOtherInformationMaturityDate", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "xtlb_IntangibleAssetsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Line Items]" } } }, "localname": "IntangibleAssetsDetailsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "xtlb_IntangibleAssetsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Table]" } } }, "localname": "IntangibleAssetsDetailsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "xtlb_IntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets [Abstract]" } } }, "localname": "IntangibleAssetsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssets" ], "xbrltype": "stringItemType" }, "xtlb_IntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets [Table]" } } }, "localname": "IntangibleAssetsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssets" ], "xbrltype": "stringItemType" }, "xtlb_InterCureLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "InterCureLtdMember", "terseLabel": "InterCure Ltd [Member]" } } }, "localname": "InterCureLtdMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "xtlb_InterestIncome": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest income.", "label": "InterestIncome", "negatedLabel": "Interest income" } } }, "localname": "InterestIncome", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_IsraeliCpiForwardContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IsraeliCpiForwardContractsMember", "terseLabel": "NIS (not linked to the Israeli CPI) [Member]" } } }, "localname": "IsraeliCpiForwardContractsMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcashandcashequivalentsaredenominatedorlinkedTable" ], "xbrltype": "domainItemType" }, "xtlb_IsraeliNewShekelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IsraeliNewShekelMember", "terseLabel": "NIS (not linked to the Israeli CPI) [Member]" } } }, "localname": "IsraeliNewShekelMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcarryingamountofotheraccountspayableTable" ], "xbrltype": "domainItemType" }, "xtlb_IssuanceDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance date.", "label": "IssuanceDate", "terseLabel": "Issuance date" } } }, "localname": "IssuanceDate", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable" ], "xbrltype": "dateItemType" }, "xtlb_Issued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued March 7,2021 due to warrant exercise.", "label": "Issued", "terseLabel": "Issued" } } }, "localname": "Issued", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "sharesItemType" }, "xtlb_IssuedAugust302021DueToWarrantExerciseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuedAugust302021DueToWarrantExerciseMember", "terseLabel": "Issued August 30, 2021 due to warrant exercise [Member]" } } }, "localname": "IssuedAugust302021DueToWarrantExerciseMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "domainItemType" }, "xtlb_IssuedJuly62021DueToWarrantExerciseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuedJuly62021DueToWarrantExerciseMember", "terseLabel": "Issued July 6, 2021 due to warrant exercise [Member]" } } }, "localname": "IssuedJuly62021DueToWarrantExerciseMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "domainItemType" }, "xtlb_IssuedMarch72021DueToWarrantExerciseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuedMarch72021DueToWarrantExerciseMember", "terseLabel": "Issued March 7,2021 due to warrant exercise [Member]" } } }, "localname": "IssuedMarch72021DueToWarrantExerciseMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "domainItemType" }, "xtlb_IssuedMay42021DueToWarrantExerciseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuedMay42021DueToWarrantExerciseMember", "terseLabel": "Issued May 4, 2021 due to warrant exercise [Member]" } } }, "localname": "IssuedMay42021DueToWarrantExerciseMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "domainItemType" }, "xtlb_IssuedOctober112021DueToWarrantExerciseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuedOctober112021DueToWarrantExerciseMember", "terseLabel": "Issued October 11, 2021 due to warrant exercise [Member]" } } }, "localname": "IssuedOctober112021DueToWarrantExerciseMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "domainItemType" }, "xtlb_IssuedOrdinarySharesAtJanuary1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued ordinary shares.", "label": "IssuedOrdinarySharesAtJanuary1", "terseLabel": "Issued ordinary shares at January 1" } } }, "localname": "IssuedOrdinarySharesAtJanuary1", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "sharesItemType" }, "xtlb_IssuedSeptember12021DueToWarrantExerciseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuedSeptember12021DueToWarrantExerciseMember", "terseLabel": "Issued September 1, 2021 due to warrant exercise [Member]" } } }, "localname": "IssuedSeptember12021DueToWarrantExerciseMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "domainItemType" }, "xtlb_LicenseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "LicenseAgreement", "terseLabel": "License agreement, description" } } }, "localname": "LicenseAgreement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "xtlb_MarchSevenTwoThousandAndSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MarchSevenTwoThousandAndSeventeenMember", "terseLabel": "March 7, 2017 [Member]" } } }, "localname": "MarchSevenTwoThousandAndSeventeenMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable", "http://xtlb.com/role/ScheduleofwarrantexercisesTable" ], "xbrltype": "domainItemType" }, "xtlb_MarketableSecuritiesInterCureLtdLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable Securities - InterCure Ltd [Abstract]" } } }, "localname": "MarketableSecuritiesInterCureLtdLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtd" ], "xbrltype": "stringItemType" }, "xtlb_MarketableSecuritiesInterCureLtdTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable Securities - InterCure Ltd [Table]" } } }, "localname": "MarketableSecuritiesInterCureLtdTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtd" ], "xbrltype": "stringItemType" }, "xtlb_MeetingAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MeetingAxis", "terseLabel": "Meeting [Axis]" } } }, "localname": "MeetingAxis", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "stringItemType" }, "xtlb_MeetingDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Meeting [Domain]" } } }, "localname": "MeetingDomain", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "domainItemType" }, "xtlb_NamePlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NamePlanAxis", "terseLabel": "Name Plan [Axis]" } } }, "localname": "NamePlanAxis", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "stringItemType" }, "xtlb_NamePlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NamePlan [Domain]" } } }, "localname": "NamePlanDomain", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "domainItemType" }, "xtlb_NumberOfOutstandingShareOptionsInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement.", "label": "NumberOfOutstandingShareOptionsInShareBasedPaymentArrangement", "periodEndLabel": "Number of options, outstanding at end of year", "periodStartLabel": "Number of options, outstanding at beginning of year" } } }, "localname": "NumberOfOutstandingShareOptionsInShareBasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfOutstandingShareOptionsInShareBasedPaymentArrangements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement.", "label": "NumberOfOutstandingShareOptionsInShareBasedPaymentArrangements", "terseLabel": "Options outstanding at end of year\t(in Shares)" } } }, "localname": "NumberOfOutstandingShareOptionsInShareBasedPaymentArrangements", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement.", "label": "NumberOfShareExercisableInSharebasedPaymentArrangement", "terseLabel": "Number of share holding of up (in Shares)" } } }, "localname": "NumberOfShareExercisableInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfShareExercisableOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement.", "label": "NumberOfShareExercisableOptionsInSharebasedPaymentArrangement", "periodEndLabel": "Number of options, exercisable at end of year" } } }, "localname": "NumberOfShareExercisableOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfShareExercisedOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement.", "label": "NumberOfShareExercisedOptionsInSharebasedPaymentArrangement", "terseLabel": "Number of options, exercised" } } }, "localname": "NumberOfShareExercisedOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfShareExpiredOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement.", "label": "NumberOfShareExpiredOptionsInSharebasedPaymentArrangement", "terseLabel": "Number of options, expired" } } }, "localname": "NumberOfShareExpiredOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfShareForfeitedOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement.", "label": "NumberOfShareForfeitedOptionsInSharebasedPaymentArrangement", "terseLabel": "Number of options, forfeited" } } }, "localname": "NumberOfShareForfeitedOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfShareGrantedOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement.", "label": "NumberOfShareGrantedOptionsInSharebasedPaymentArrangement", "terseLabel": "Number of options, granted" } } }, "localname": "NumberOfShareGrantedOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfShareWarrantsExercisedInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Share Warrants Exercised In Sharebased Payment Arrangement.", "label": "NumberOfShareWarrantsExercisedInSharebasedPaymentArrangement", "terseLabel": "Outstanding warrants" } } }, "localname": "NumberOfShareWarrantsExercisedInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumberOfSharesAbstract", "terseLabel": "Number of shares" } } }, "localname": "NumberOfSharesAbstract", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "stringItemType" }, "xtlb_NumberOfSharesAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumberOfSharesAbstract0", "terseLabel": "Number of shares" } } }, "localname": "NumberOfSharesAbstract0", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesdilutedTable" ], "xbrltype": "stringItemType" }, "xtlb_NumberOfSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumberOfSharesMember", "terseLabel": "Number of shares [Member]" } } }, "localname": "NumberOfSharesMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesdilutedTable" ], "xbrltype": "domainItemType" }, "xtlb_NumberOfWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised.", "label": "NumberOfWarrantsExercised", "terseLabel": "Number of warrants, exercised (in Dollars per share)" } } }, "localname": "NumberOfWarrantsExercised", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantexercisesTable" ], "xbrltype": "perShareItemType" }, "xtlb_NumberOfWarrantsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants outstanding.", "label": "NumberOfWarrantsOutstanding", "periodEndLabel": "Number of warrants outstanding, ending balance", "periodStartLabel": "Number of warrants outstanding, beginning balance" } } }, "localname": "NumberOfWarrantsOutstanding", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantexercisesTable" ], "xbrltype": "sharesItemType" }, "xtlb_OptionExercisedInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Share Option Exercised In Sharebased Payment Arrangement.", "label": "OptionExercisedInSharebasedPaymentArrangement", "terseLabel": "Outstanding options" } } }, "localname": "OptionExercisedInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "xtlb_OptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options outstanding.", "label": "OptionsOutstanding", "terseLabel": "Options outstanding" } } }, "localname": "OptionsOutstanding", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "sharesItemType" }, "xtlb_OrdinarySharesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares, description.", "label": "OrdinarySharesDescription", "terseLabel": "Ordinary shares, description" } } }, "localname": "OrdinarySharesDescription", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "stringItemType" }, "xtlb_PatentsAndFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expenses for patents and fees.", "label": "PatentsAndFees", "terseLabel": "Patents and fees" } } }, "localname": "PatentsAndFees", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "xtlb_PercentageOfHoldingShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of holding shares.", "label": "PercentageOfHoldingShare", "terseLabel": "Percentage of shares hold" } } }, "localname": "PercentageOfHoldingShare", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails" ], "xbrltype": "percentItemType" }, "xtlb_PercentageOfObligationToPayRoyalties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of obligation to pay royalties.", "label": "PercentageOfObligationToPayRoyalties", "terseLabel": "Percentage of obligation to pay royalties" } } }, "localname": "PercentageOfObligationToPayRoyalties", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/CommitmentsDetails" ], "xbrltype": "percentItemType" }, "xtlb_PercentageOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares.", "label": "PercentageOfShare", "terseLabel": "Percentage of shares" } } }, "localname": "PercentageOfShare", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "xtlb_PrepaidExpensesandOtherCurrentAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Abstract]" } } }, "localname": "PrepaidExpensesandOtherCurrentAssetsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/PrepaidExpensesandOtherCurrentAssets" ], "xbrltype": "stringItemType" }, "xtlb_PrepaidExpensesandOtherCurrentAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Table]" } } }, "localname": "PrepaidExpensesandOtherCurrentAssetsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/PrepaidExpensesandOtherCurrentAssets" ], "xbrltype": "stringItemType" }, "xtlb_PropertyAndEquipmentUsefulLifePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property and equipment useful life, percentage.", "label": "PropertyAndEquipmentUsefulLifePercentage", "terseLabel": "Property and equipment useful life, percentage" } } }, "localname": "PropertyAndEquipmentUsefulLifePercentage", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "percentItemType" }, "xtlb_RangeOfExercisePricesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RangeOfExercisePricesOneMember", "terseLabel": "Range of Exercise Prices One [Member]" } } }, "localname": "RangeOfExercisePricesOneMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable" ], "xbrltype": "domainItemType" }, "xtlb_RangeOfExercisePricesTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RangeOfExercisePricesTwoMember", "terseLabel": "Range of Exercise Prices Two [Member]" } } }, "localname": "RangeOfExercisePricesTwoMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable" ], "xbrltype": "domainItemType" }, "xtlb_ReceiptOfRequiredInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receipt of required investment.", "label": "ReceiptOfRequiredInvestment", "terseLabel": "Receipt of required investment" } } }, "localname": "ReceiptOfRequiredInvestment", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_RemainingLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remaining liability.", "label": "RemainingLiability", "terseLabel": "Remaining liability" } } }, "localname": "RemainingLiability", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_RentAndOfficeMaintenance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense rent and office maintenance.", "label": "RentAndOfficeMaintenance", "terseLabel": "Rent and office maintenance" } } }, "localname": "RentAndOfficeMaintenance", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "xtlb_RentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of rent expenses.", "label": "RentExpense", "terseLabel": "Rent paid" } } }, "localname": "RentExpense", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_RepaymentOfShort-TermBankDeposit": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Repayment of short-term bank deposit.", "label": "RepaymentOfShort-TermBankDeposit", "terseLabel": "Repayment of short-term bank deposit" } } }, "localname": "RepaymentOfShort-TermBankDeposit", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_RevaluationMarketableSecurities": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revaluation of marketable securities", "label": "RevaluationMarketableSecurities", "terseLabel": "Revaluation of marketable securities" } } }, "localname": "RevaluationMarketableSecurities", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "xtlb_RevaluationOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": -1.0 }, "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revaluable of marketable securites.", "label": "RevaluationOfMarketableSecurities", "negatedLabel": "Revaluation of marketable securities - InterCure Ltd", "terseLabel": "Revaluation of marketable securities \u2013 InterCure Ltd" } } }, "localname": "RevaluationOfMarketableSecurities", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow", "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "xtlb_RevaluationOfWarrantsToPurchase": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revaluation of warrants to purchase .", "label": "RevaluationOfWarrantsToPurchase", "terseLabel": "Revaluation of warrants to purchase ADS\u2019s" } } }, "localname": "RevaluationOfWarrantsToPurchase", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_RevaluationOfWarrantsToPurchaseADSs": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "RevaluationOfWarrantsToPurchaseADSs", "terseLabel": "Revaluation of warrants to purchase ADS\u2019s" } } }, "localname": "RevaluationOfWarrantsToPurchaseADSs", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "xtlb_RevaluationOfWarrantsToPurchaseAds": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revaluation of warrants to purchase ads.", "label": "RevaluationOfWarrantsToPurchaseAds", "terseLabel": "Revaluation of warrants to purchase ADS\u2019s" } } }, "localname": "RevaluationOfWarrantsToPurchaseAds", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "xtlb_RevaluationOfWarrantsToPurchaseExpenses": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable": { "order": 1.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "RevaluationOfWarrantsToPurchaseExpenses", "terseLabel": "Revaluation of warrants to purchase ADS\u2019s" } } }, "localname": "RevaluationOfWarrantsToPurchaseExpenses", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoffinanceincomeexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of carrying amount of other accounts payable [Abstract]" } } }, "localname": "ScheduleOfCarryingAmountOfOtherAccountsPayableAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of carrying amount of other accounts payable Text Block", "label": "ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock", "terseLabel": "Schedule of carrying amount of other accounts payable" } } }, "localname": "ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/AccountsPayableTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of cash and cash equivalents [Abstract]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of cash and cash equivalents are denominated or linked [Abstract]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfChangesInFinancialLiabilitiesFromFinanceActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of changes in financial liabilities from finance activities [Abstract]" } } }, "localname": "ScheduleOfChangesInFinancialLiabilitiesFromFinanceActivitiesAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfChangesInMarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of changes in marketable securities [Abstract]" } } }, "localname": "ScheduleOfChangesInMarketableSecuritiesAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of compensation to key management personnel for employee services [Abstract]" } } }, "localname": "ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfCompositionOfAccountsPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of composition of accounts payable [Abstract]" } } }, "localname": "ScheduleOfCompositionOfAccountsPayableAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of composition of accounts payable Text Block", "label": "ScheduleOfCompositionOfAccountsPayableTextBlock", "terseLabel": "Schedule of composition of accounts payable" } } }, "localname": "ScheduleOfCompositionOfAccountsPayableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/AccountsPayableTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfDepreciationOfPropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of depreciation of property and equipment [Abstract]" } } }, "localname": "ScheduleOfDepreciationOfPropertyAndEquipmentAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfDetailedInformationAboutTheFairValueForOptionsGrantedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of detailed information about the fair value for options granted [Abstract]" } } }, "localname": "ScheduleOfDetailedInformationAboutTheFairValueForOptionsGrantedAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The table disclose the finance income (cost) for during the period.", "label": "ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock", "terseLabel": "Schedule of finance income (expenses), net" } } }, "localname": "ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/FinanceIncomeExpensesNetTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfExchangeRateOfTheUSDollarInRelationToTheNisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of exchange rate of the U.S. dollar in relation to the NIS [Abstract]" } } }, "localname": "ScheduleOfExchangeRateOfTheUSDollarInRelationToTheNisAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfExercisePriceAndTheRemainingContractualLifeInYearsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of exercise price and the remaining contractual life (in years) [Abstract]" } } }, "localname": "ScheduleOfExercisePriceAndTheRemainingContractualLifeInYearsAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of finance income (expenses), net [Abstract]" } } }, "localname": "ScheduleOfFinanceIncomeExpensesNetAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of financial instruments [Abstract]" } } }, "localname": "ScheduleOfFinancialInstrumentsAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfGeneralAndAdministrativeExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of general and administrative expenses [Abstract]" } } }, "localname": "ScheduleOfGeneralAndAdministrativeExpensesAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfIncomeTaxExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The table disclose the income tax reconciliation.", "label": "ScheduleOfIncomeTaxExplanatoryTableTextBlock", "terseLabel": "Schedule of reconciliation between the \u201ctheoretical\u201d tax expense" } } }, "localname": "ScheduleOfIncomeTaxExplanatoryTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of number of share options and their related weighted average exercise prices [Abstract]" } } }, "localname": "ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfOutstandingOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of outstanding options [Abstract]" } } }, "localname": "ScheduleOfOutstandingOptionsAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of prepaid expenses and other current assets [Abstract]" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of profit (loss) attributed to ordinary shareholders (basic) [Abstract]" } } }, "localname": "ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of profit (loss) attributed to ordinary shareholders (diluted) [Abstract]" } } }, "localname": "ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersbasicTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfProfitlossAttributedToOrdinaryShareholdersbasicTableTextBlock", "terseLabel": "Schedule of profit (loss) attributed to ordinary shareholders (basic)" } } }, "localname": "ScheduleOfProfitlossAttributedToOrdinaryShareholdersbasicTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of profit (loss) attributed to ordinary shareholders (diluted).", "label": "ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock", "terseLabel": "Schedule of profit (loss) attributed to ordinary shareholders (diluted)" } } }, "localname": "ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfReconciliationBetweenTheTheoreticalTaxExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation between the \u201ctheoretical\u201d tax expense [Abstract]" } } }, "localname": "ScheduleOfReconciliationBetweenTheTheoreticalTaxExpenseAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of research and development expenses [Abstract]" } } }, "localname": "ScheduleOfResearchAndDevelopmentExpensesAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share based payments award stock warrats valuation assumptions.", "label": "ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "terseLabel": "Schedule of warrants valuation assumptions of investors' warrants" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfTheOutstandingWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of the outstanding warrants [Abstract]" } } }, "localname": "ScheduleOfTheOutstandingWarrantsAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfTheOutstandingWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of schedule of the outstanding warrants table.", "label": "ScheduleOfTheOutstandingWarrantsTableTextBlock", "terseLabel": "Schedule of the outstanding warrants" } } }, "localname": "ScheduleOfTheOutstandingWarrantsTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfWarrantExercisesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrant exercises [Abstract]" } } }, "localname": "ScheduleOfWarrantExercisesAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfWarrantExercisesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfWarrantExercisesTableTextBlock", "terseLabel": "Schedule of warrant exercises" } } }, "localname": "ScheduleOfWarrantExercisesTableTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfWarrantsValuationAssumptionsOfInvestorsWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrants valuation assumptions of investors' warrants [Abstract]" } } }, "localname": "ScheduleOfWarrantsValuationAssumptionsOfInvestorsWarrantsAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of weighted-average number of ordinary shares (basic) [Abstract]" } } }, "localname": "ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of weighted-average number of ordinary shares (diluted) [Abstract]" } } }, "localname": "ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesbasicTableTexBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of weighted-average number of ordinary shares (basic).", "label": "ScheduleOfWeightedaverageNumberOfOrdinarySharesbasicTableTexBlock", "terseLabel": "Schedule of weighted-average number of ordinary shares (basic)" } } }, "localname": "ScheduleOfWeightedaverageNumberOfOrdinarySharesbasicTableTexBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of weighted-average number of ordinary shares (diluted).", "label": "ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock", "terseLabel": "Schedule of weighted-average number of ordinary shares (diluted)" } } }, "localname": "ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDate", "terseLabel": "Grant date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDate", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "dateItemType" }, "xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice", "terseLabel": "Exercise price in NIS" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "perShareItemType" }, "xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInPeriodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sets forth the nature of any other increase or decrease in the number of shares reserved for issuance under the option plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInPeriodDescription", "terseLabel": "Vesting schedule" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInPeriodDescription", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue", "terseLabel": "Fair value USD in thousands" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "monetaryItemType" }, "xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options position.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition", "terseLabel": "Position" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) [Line Items]" } } }, "localname": "ShareBasedPaymentDetailsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) - Schedule of detailed information about the fair value for options granted [Line Items]" } } }, "localname": "ShareBasedPaymentDetailsScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) - Schedule of detailed information about the fair value for options granted [Table]" } } }, "localname": "ShareBasedPaymentDetailsScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofdetailedinformationaboutthefairvalueforoptionsgrantedTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsScheduleofexercisepriceandtheremainingcontractuallifeinyearsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) - Schedule of exercise price and the remaining contractual life (in years) [Line Items]" } } }, "localname": "ShareBasedPaymentDetailsScheduleofexercisepriceandtheremainingcontractuallifeinyearsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) - Schedule of exercise price and the remaining contractual life (in years) [Table]" } } }, "localname": "ShareBasedPaymentDetailsScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) - Schedule of number of share options and their related weighted average exercise prices [Line Items]" } } }, "localname": "ShareBasedPaymentDetailsScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) - Schedule of number of share options and their related weighted average exercise prices [Table]" } } }, "localname": "ShareBasedPaymentDetailsScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsScheduleofoutstandingoptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) - Schedule of outstanding options [Line Items]" } } }, "localname": "ShareBasedPaymentDetailsScheduleofoutstandingoptionsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsScheduleofoutstandingoptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) - Schedule of outstanding options [Table]" } } }, "localname": "ShareBasedPaymentDetailsScheduleofoutstandingoptionsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment (Details) [Table]" } } }, "localname": "ShareBasedPaymentDetailsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based payment transactions to employees and non-employees.", "label": "ShareBasedPaymentTransactionsToEmployeesAndNonEmployees", "terseLabel": "Share-based payment transactions to employees and non-employees", "verboseLabel": "Net expenses recognized for grant of options to employees" } } }, "localname": "ShareBasedPaymentTransactionsToEmployeesAndNonEmployees", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow", "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_ShareCapitalReservesAndRetainedEarnings": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareCapitalReservesAndRetainedEarnings", "terseLabel": "SHARE CAPITAL, RESERVES AND RETAINED EARNINGS" } } }, "localname": "ShareCapitalReservesAndRetainedEarnings", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareCapitalReservesandRetainedEarnings" ], "xbrltype": "textBlockItemType" }, "xtlb_ShareCapitalReservesAndRetainedEarningsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital Reserves And Retained Earnings [Abstract]" } } }, "localname": "ShareCapitalReservesAndRetainedEarningsAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_ShareCapitalReservesandRetainedEarningsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital, Reserves and Retained Earnings (Details) [Line Items]" } } }, "localname": "ShareCapitalReservesandRetainedEarningsDetailsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "stringItemType" }, "xtlb_ShareCapitalReservesandRetainedEarningsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital, Reserves and Retained Earnings (Details) [Table]" } } }, "localname": "ShareCapitalReservesandRetainedEarningsDetailsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareCapitalReservesandRetainedEarningsDetails" ], "xbrltype": "stringItemType" }, "xtlb_SharebasedPaymentAwardRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased payment award remaining contractual term for the during the period.", "label": "SharebasedPaymentAwardRemainingContractualTerm", "terseLabel": "Share based payment award remaining contractual term" } } }, "localname": "SharebasedPaymentAwardRemainingContractualTerm", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "durationItemType" }, "xtlb_SignificantAccountingPoliciesDetailsScheduleofdepreciationofpropertyandequipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment [Line Items]" } } }, "localname": "SignificantAccountingPoliciesDetailsScheduleofdepreciationofpropertyandequipmentLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "xtlb_SignificantAccountingPoliciesDetailsScheduleofdepreciationofpropertyandequipmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) - Schedule of depreciation of property and equipment [Table]" } } }, "localname": "SignificantAccountingPoliciesDetailsScheduleofdepreciationofpropertyandequipmentTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofdepreciationofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "xtlb_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StockOptionsMember", "terseLabel": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable", "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable", "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "xtlb_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "xtlb_TaxEffectOfExpensesNotDeductibleInDeterminingTaxableProfitTaxLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]", "label": "TaxEffectOfExpensesNotDeductibleInDeterminingTaxableProfitTaxLoss", "terseLabel": "Expenses (income) not recognized for tax purposes" } } }, "localname": "TaxEffectOfExpensesNotDeductibleInDeterminingTaxableProfitTaxLoss", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofreconciliationbetweenthetheoreticaltaxexpenseTable" ], "xbrltype": "monetaryItemType" }, "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total amount of income and expenses not involving cash flows", "label": "TotalIncomeAndExpensesNotInvolvingCashFlows", "totalLabel": "Net income and expenses not involving cash flows" } } }, "localname": "TotalIncomeAndExpensesNotInvolvingCashFlows", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transactions and Balances with Related Parties (Details) [Line Items]" } } }, "localname": "TransactionsandBalanceswithRelatedPartiesDetailsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transactions and Balances with Related Parties (Details) [Table]" } } }, "localname": "TransactionsandBalanceswithRelatedPartiesDetailsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "xtlb_TwoDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TwoDirectorsMember", "terseLabel": "Two Directors [Member]" } } }, "localname": "TwoDirectorsMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingoptionsTable" ], "xbrltype": "domainItemType" }, "xtlb_TwoThousandElevenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TwoThousandElevenPlanMember", "terseLabel": "Two Thousand Eleven Plan [Member]" } } }, "localname": "TwoThousandElevenPlanMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "domainItemType" }, "xtlb_TypeOfCurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypeOfCurrencyAxis", "terseLabel": "Type Of Currency [Axis]" } } }, "localname": "TypeOfCurrencyAxis", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcarryingamountofotheraccountspayableTable" ], "xbrltype": "stringItemType" }, "xtlb_TypeOfCurrencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypeOfCurrency [Domain]" } } }, "localname": "TypeOfCurrencyDomain", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcarryingamountofotheraccountspayableTable" ], "xbrltype": "domainItemType" }, "xtlb_UnitedStatesDollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UnitedStatesDollarMember", "terseLabel": "U.S. dollars [Member]" } } }, "localname": "UnitedStatesDollarMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofcarryingamountofotheraccountspayableTable" ], "xbrltype": "domainItemType" }, "xtlb_UnvestedOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unvested options.", "label": "UnvestedOptions", "terseLabel": "Unvested options" } } }, "localname": "UnvestedOptions", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ShareBasedPaymentDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_ValueInUSDperWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value in usd.", "label": "ValueInUSDperWarrant", "terseLabel": "Value in USD (per warrant)" } } }, "localname": "ValueInUSDperWarrant", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable" ], "xbrltype": "perShareItemType" }, "xtlb_ValueInUSDperWarrantExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value in usd per warrant exercised.", "label": "ValueInUSDperWarrantExercised", "terseLabel": "Value in USD (per warrant), exercised (in Dollars per share)" } } }, "localname": "ValueInUSDperWarrantExercised", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantexercisesTable" ], "xbrltype": "perShareItemType" }, "xtlb_ValueInUSDperWarrantOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value in usd per warrant outstanding.", "label": "ValueInUSDperWarrantOutstanding", "periodEndLabel": "Value in USD (per warrant), outstanding ending balance", "periodStartLabel": "Value in USD (per warrant), outstanding beginning balance" } } }, "localname": "ValueInUSDperWarrantOutstanding", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantexercisesTable" ], "xbrltype": "sharesItemType" }, "xtlb_WarrantRevaluationIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrant revaluation income.", "label": "WarrantRevaluationIncome", "terseLabel": "Warrant revaluation income" } } }, "localname": "WarrantRevaluationIncome", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofprofitlossattributedtoordinaryshareholdersdilutedTable" ], "xbrltype": "monetaryItemType" }, "xtlb_Warrants": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrants", "terseLabel": "Warrants" } } }, "localname": "Warrants", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "xtlb_WarrantsAtFairValueOfExplanatoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants At Fair Value Of Explanatory [Abstract]" } } }, "localname": "WarrantsAtFairValueOfExplanatoryAbstract", "nsuri": "http://xtlb.com/20211231", "xbrltype": "stringItemType" }, "xtlb_WarrantsAtFairValueOfExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for warrants at fair value of explanatory.", "label": "WarrantsAtFairValueOfExplanatoryTextBlock", "terseLabel": "WARRANTS" } } }, "localname": "WarrantsAtFairValueOfExplanatoryTextBlock", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "xtlb_WarrantsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) [Line Items]" } } }, "localname": "WarrantsDetailsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleoftheoutstandingwarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of the outstanding warrants [Line Items]" } } }, "localname": "WarrantsDetailsScheduleoftheoutstandingwarrantsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleoftheoutstandingwarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of the outstanding warrants [Table]" } } }, "localname": "WarrantsDetailsScheduleoftheoutstandingwarrantsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleofwarrantexercisesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of warrant exercises [Line Items]" } } }, "localname": "WarrantsDetailsScheduleofwarrantexercisesLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantexercisesTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleofwarrantexercisesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of warrant exercises [Table]" } } }, "localname": "WarrantsDetailsScheduleofwarrantexercisesTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantexercisesTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleofwarrantsvaluationassumptionsofinvestorswarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants [Line Items]" } } }, "localname": "WarrantsDetailsScheduleofwarrantsvaluationassumptionsofinvestorswarrantsLineItems", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants [Table]" } } }, "localname": "WarrantsDetailsScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) [Table]" } } }, "localname": "WarrantsDetailsTable", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants expired.", "label": "WarrantsExpired", "terseLabel": "Warrants expired" } } }, "localname": "WarrantsExpired", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "xtlb_WarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsIssued", "terseLabel": "Warrants issued" } } }, "localname": "WarrantsIssued", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "xtlb_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsMember", "terseLabel": "Warrants" } } }, "localname": "WarrantsMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofchangesinfinancialliabilitiesfromfinanceactivitiesTable" ], "xbrltype": "domainItemType" }, "xtlb_WarrantsOutstandingToPurchaseADSs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants outstanding to purchase.", "label": "WarrantsOutstandingToPurchaseADSs", "terseLabel": "Warrants outstanding to purchase ADSs (in Shares)" } } }, "localname": "WarrantsOutstandingToPurchaseADSs", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable" ], "xbrltype": "sharesItemType" }, "xtlb_WeightedAverageExercisePriceOfExercisableShareOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]", "label": "WeightedAverageExercisePriceOfExercisableShareOptionsInSharebasedPaymentArrangement", "periodEndLabel": "Weighted average exercise price, exercisable at end of year" } } }, "localname": "WeightedAverageExercisePriceOfExercisableShareOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "perShareItemType" }, "xtlb_WeightedAverageExercisePriceOfShareExercisedOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]].", "label": "WeightedAverageExercisePriceOfShareExercisedOptionsInSharebasedPaymentArrangement", "terseLabel": "Weighted average exercise price, exercised" } } }, "localname": "WeightedAverageExercisePriceOfShareExercisedOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "perShareItemType" }, "xtlb_WeightedAverageExercisePriceOfShareExpiredOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]].", "label": "WeightedAverageExercisePriceOfShareExpiredOptionsInSharebasedPaymentArrangement", "terseLabel": "Weighted average exercise price, expired" } } }, "localname": "WeightedAverageExercisePriceOfShareExpiredOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "perShareItemType" }, "xtlb_WeightedAverageExercisePriceOfShareForfeitedOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]].", "label": "WeightedAverageExercisePriceOfShareForfeitedOptionsInSharebasedPaymentArrangement", "terseLabel": "Weighted average exercise price, forfeited" } } }, "localname": "WeightedAverageExercisePriceOfShareForfeitedOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "perShareItemType" }, "xtlb_WeightedAverageExercisePriceOfShareGrantedOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]].", "label": "WeightedAverageExercisePriceOfShareGrantedOptionsInSharebasedPaymentArrangement", "terseLabel": "Weighted average exercise price, granted" } } }, "localname": "WeightedAverageExercisePriceOfShareGrantedOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "perShareItemType" }, "xtlb_WeightedAverageNumberOfOrdinarySharesbasic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average number of ordinary shares (basic).\r \n.", "label": "WeightedAverageNumberOfOrdinarySharesbasic", "terseLabel": "Weighted average number of ordinary shares (basic)" } } }, "localname": "WeightedAverageNumberOfOrdinarySharesbasic", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesbasicTable" ], "xbrltype": "sharesItemType" }, "xtlb_WeightedAverageNumberOfOrdinarySharesdiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average number of ordinary shares (diluted).\r \n.", "label": "WeightedAverageNumberOfOrdinarySharesdiluted", "terseLabel": "Weighted average number of ordinary shares (diluted)" } } }, "localname": "WeightedAverageNumberOfOrdinarySharesdiluted", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesdilutedTable" ], "xbrltype": "sharesItemType" }, "xtlb_WeightedAverageOutstandingExercisePriceOfShareOptionsInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]].", "label": "WeightedAverageOutstandingExercisePriceOfShareOptionsInSharebasedPaymentArrangement", "periodEndLabel": "Weighted average exercise price, outstanding at end of year", "periodStartLabel": "Weighted average exercise price, outstanding at beginning of year" } } }, "localname": "WeightedAverageOutstandingExercisePriceOfShareOptionsInSharebasedPaymentArrangement", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofnumberofshareoptionsandtheirrelatedweightedaverageexercisepricesTable" ], "xbrltype": "perShareItemType" }, "xtlb_WeightedAverageRemainingContractualLifeOfShareOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]].", "label": "WeightedAverageRemainingContractualLifeOfShareOptionsOutstanding", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "WeightedAverageRemainingContractualLifeOfShareOptionsOutstanding", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofexercisepriceandtheremainingcontractuallifeinyearsTable" ], "xbrltype": "durationItemType" }, "xtlb_WeightedaverageNumberOfOrdinarySharesbasic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average number of ordinary shares (basic).", "label": "WeightedaverageNumberOfOrdinarySharesbasic", "terseLabel": "Weighted-average number of ordinary shares (basic)" } } }, "localname": "WeightedaverageNumberOfOrdinarySharesbasic", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofweightedaveragenumberofordinarysharesdilutedTable" ], "xbrltype": "sharesItemType" }, "xtlb_YedaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "YedaMember", "terseLabel": "Yeda [Member]" } } }, "localname": "YedaMember", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "xtlb_comprehensiveIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "comprehensive income.", "label": "comprehensiveIncome", "terseLabel": "comprehensive income" } } }, "localname": "comprehensiveIncome", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleofprofitlossattributedtoordinaryshareholdersdilutedTable" ], "xbrltype": "monetaryItemType" }, "xtlb_full_ExercisePriceOfOutstandingShareOptions2019": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The exercise price of outstanding share options.", "label": "full_ExercisePriceOfOutstandingShareOptions2019", "terseLabel": "Number of shares exercisable" } } }, "localname": "full_ExercisePriceOfOutstandingShareOptions2019", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/ScheduleoftheoutstandingwarrantsTable" ], "xbrltype": "perShareItemType" }, "xtlb_warrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "warrants.", "label": "warrants", "terseLabel": "warrants" } } }, "localname": "warrants", "nsuri": "http://xtlb.com/20211231", "presentation": [ "http://xtlb.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24" }, "r102": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24" }, "r103": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24" }, "r104": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r106": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B33&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r107": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Hedge accounting", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g21A-24G_TI", "URIDate": "2021-03-24" }, "r108": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r111": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r113": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r116": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r117": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r118": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r119": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_d&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r121": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r122": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r123": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r124": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r125": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "70", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard", "URIDate": "2021-03-24" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r22": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2021-03-24" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_b&doctype=Standard", "URIDate": "2021-03-24" }, "r3": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r32": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2021-03-24" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18A&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24" }, "r51": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_v&doctype=Standard", "URIDate": "2021-03-24" }, "r53": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r6": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "46", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_46&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r78": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r79": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r81": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r82": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r84": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r85": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r87": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "105", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard", "URIDate": "2021-03-24" }, "r93": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard", "URIDate": "2021-03-24" }, "r95": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r97": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r98": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r99": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" } }, "version": "2.1" }